AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical ...
AEON Biopharma, Inc. (NYSE American: AEON) is a clinical-stage biopharmaceutical company dedicated to expanding the therapeutic use of botulinum toxins. Founded in 2012 as Alphaeon Corporation and renamed in 2019, the company is headquartered in Irvine, California. AEON's primary focus is on developing ABP-450 (prabotulinumtoxinA), a 900 kDa botulinum toxin ...AEON Biopharma, Inc. (NYSE American: AEON) is a clinical-stage biopharmaceutical company dedicated to expanding the therapeutic use of botulinum toxins. Founded in 2012 as Alphaeon Corporation and renamed in 2019, the company is headquartered in Irvine, California. AEON's primary focus is on developing ABP-450 (prabotulinumtoxinA), a 900 kDa botulinum toxin complex, for the treatment of various neurological and gastrointestinal disorders. The company aims to achieve full-label access to the U.S. therapeutic neurotoxin market by demonstrating biosimilarity to BOTOX®, which could offer more affordable treatment options.\n\nABP-450 is currently in clinical development for indications such as chronic migraine, cervical dystonia, and gastroparesis. The company has conducted clinical trials to support its efficacy and safety profile, and it continues to advance its pipeline. The therapeutic botulinum toxin market is competitive, with established players like Allergan (BOTOX) and emerging biosimilars, but AEON's focused approach and potential cost-effectiveness could position it as a significant competitor.\n\nFinancially, AEON is in the clinical stage with no revenue, as it has not yet commercialized any products. The company's financial metrics reflect its development stage: negative net income, negative operating cash flow, and no revenue. As of the latest snapshot, the market cap is approximately $12.1 million, with a stock price of $0.275. The company has a low enterprise value, and its financial leverage is negative due to negative shareholder equity. AEON relies on funding through stock offerings and partnerships to support its R&D activities.\n\nThe management team is led by President and CEO Robert Bancroft, who brings over 25 years of leadership experience in the life sciences sector, including roles at Revance Therapeutics and QMENTA. CFO John Bencich and Chief Legal & Strategy Officer Alex Wilson support the executive team. The company has a small team of 8 employees as of the latest data, reflecting its lean clinical-stage operations.\n\nLooking ahead, AEON Biopharma aims to continue clinical development, potentially seeking regulatory approvals for ABP-450. The company's success will depend on clinical trial outcomes, regulatory pathways, and its ability to secure additional financing. Its long-term vision is to unlock the full potential of therapeutic botulinum toxins to improve the lives of patients with debilitating neuromuscular disorders.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-39.2M
-193.4%
+90.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-17.3M
+14.7%
-40.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-65.0%
-43.3%
-15.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.49x
+338.4%
-45.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
